Federal Register #FDA-2025-D-6130

FDA Draft Guidance on Impurity Specifications for Antibiotics (Informational Notice)

This notice from the Food and Drug Administration (FDA) announces the release of a draft guidance for industry regarding impurity specifications for antibiotics. - Government Buyer: - Department of Health and Human Services - Food and Drug Administration (FDA) - Center for Drug Evaluation and Research - Purpose: - Provides recommendations for setting specifications for organic impurities in antibiotics manufactured by fermentation and semi-synthesis - Applies to antibiotics under new drug applications (NDAs), abbreviated new drug applications (ANDAs), type II drug substance drug master files (DMFs), and over-the-counter (OTC) monograph drugs - Aims to clarify effective control strategies and promote consistent quality standards for antibiotic products - No OEMs, vendors, or specific products/services are being procured or awarded - This is an informational regulatory notice, not a procurement opportunity

Description

The FDA has announced the availability of a draft guidance for industry titled "Establishing Impurity Specifications for Antibiotics." This guidance provides recommendations for setting specifications for organic impurities in antibiotics produced by fermentation and semi-synthesis. It applies to antibiotics under new drug applications (NDAs), abbreviated new drug applications (ANDAs), associated drug master files (DMFs), and over-the-counter (OTC) monograph drugs. The guidance aims to clarify control strategies, support high-quality antibiotic development, and promote consistent quality standards.

View original listing